Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04879030
Other study ID # HPMU.01.04.21
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received
Last updated
Start date January 1, 2020
Est. completion date December 30, 2020

Study information

Verified date February 2020
Source Haiphong University of Medicine and Pharmacy
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators hypothesized that the empirical use of fluoroquinolones together with beta-lactam antibiotics will change their therapeutic success in patients with acute exacerbations of COPD compared to that in patients in whom a single beta-lactam treatment was used. The main goal of this study was to compare the clinical and bacterial success from the use of a combination of beta-lactam and fluoroquinolone antibiotics with that of a single beta-lactam treatment, in adult patients with COPD exacerbations.


Description:

The study protocols were reviewed and approved by the Hai Phong International Hospital Institutional Review Board, Vietnam. The study was conducted in accordance with the Declaration of Helsinki and the International Conference on the Harmonization of the Technical Requirements for the Registration of Pharmaceuticals for Human Use - Good Clinical Practice guidelines. All subjects gave written informed consent before study initiation. The participants consisted of patients aged over 45 years, diagnosed with COPD stages I-IV as stated by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 13, with acute exacerbations (onset of signs under 14 days as defined by Anthonisen et al. 14: type 1 [increased dyspnea, increased sputum volume, and sputum purulence] or type 2 [involved two or three symptoms that needed hospitalization]), the incompetence to use medication by mouth, fever (temperature over 38.5°C), antibiotic usage for longer than 1 day, treatment with systemic administration of corticosteroids (dosage equivalent to more than 30 mg of prednisolon over four days), signs of pneumonia on radiographs, history of mechanical ventilation during acute exacerbations of COPD in the past, recently detected or unresolved pulmonary malignancy, other infectious diseases requiring antibiotic treatment, and kidney failure. Randomization and Intervention This was an open-label, randomized study using two types of treatments. Participants were divided into two groups using a randomization procedure. Within 24 hours of admission, patients were assigned randomly to two groups, one to receive a course of single-antibiotic therapy with only beta-lactam antibiotics and the other to get concomitant antibiotic treatment, defined as the use of two antibiotics, including one beta-lactam antibiotic and one fluoroquinolone. The beta-lactam antibiotics with activity against gram-negative bacilli in this study included piperacillin-tazobactam, ticarcillin-clavulanate, imipenem-cilastin, meropenem, ertapenem, ceftazidime, ceftriaxone, cefotaxime, and cefixime. The fluoroquinolone antibiotics included ciprofloxacin, levofloxacin, and moxifloxacin. The other COPD medications were continued. When antibiotic therapy failed, the attending physician had the right to reevaluate the clinical status and to replace the antibiotic therapy in the study with a more appropriate treatment. Safety was recorded daily with the support of a clinical pharmacist to report adverse events. Patient data is stored in electronic medical records. Outcomes and Follow-Up On days 1, 10, and 20, patients were evaluated clinically, and blood was drawn, collected and the levels of C-reactive protein (CRP, Beckman Coulter Inc., Fullerton, CA) measured. Pulmonary function testing was done and expectorated sputum samples were collected. The symptoms were scored by using the visual analogue scale (VAS) for shortness of breath, tiredness, cough, and sputum color. The specific scores for each symptom ranged from 1 to 10 15. Separate and total scores were calculated. The primary endpoint was a clinical outcome on day 20, as stated by Chow et al. 16. Successful treatment was defined as a cure (completely resolved signs and symptoms related to exacerbations) or improvement (resolved or decreased symptoms and signs without new symptoms or signs related to infection). Treatment failure was defined as the failure to address symptoms and signs, worsening of symptoms and signs, the appearance of new symptoms and signs related to the primary or a new infection, or death. Secondary endpoints included clinical outcome on day 10 and clinical success on days 10 and 20, based on lung function (forced expiratory volume in one second [FEV1]), serum CRP, symptoms, and microbiological responses.


Recruitment information / eligibility

Status Completed
Enrollment 170
Est. completion date December 30, 2020
Est. primary completion date August 30, 2020
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - diagnosed with COPD stages I-IV with acute exacerbations - incompetence to use medication by mouth - fever - antibiotic usage for longer than 1 day - treatment with systemic administration of corticosteroids - signs of pneumonia on radiographs - history of mechanical ventilation during acute exacerbations of COPD in the past Exclusion Criteria: - recently detected or unresolved pulmonary malignancy - other infectious diseases requiring antibiotic treatment - kidney failure

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Beta-Lactams
The patient was randomized to use beta-lactams antibiotic
Fluoroquinolone
The patient was indicated to use a combination of beta-lactams and fluoroquinolones

Locations

Country Name City State
Vietnam Haiphong International Hospital H?i Phòng

Sponsors (1)

Lead Sponsor Collaborator
Haiphong University of Medicine and Pharmacy

Country where clinical trial is conducted

Vietnam, 

Outcome

Type Measure Description Time frame Safety issue
Primary clinical success on day 20 Proportion of patients were clinically successful on day 20 (%) on day 20
Primary FEV1 on day 20 Percent Predicted forced expiratory volume in one second on day 20 [FEV1] (%) on day 20
Primary FVC on day 20 Percent Predicted forced vital capacity (FVC) on day 20 (%) on day 20
Primary serum CRP on day 20 Concentration of serum CRP on day 20 (mg/L) on day 20
Primary WBC on day 20 white blood cell count on day 20 (10x109/L) on day 20
Primary microbiological success on day 20 The number of patients with success on microbiological outcomes on day 20 on day 20
Primary VAS on day 20 the visual analogue scale (VAS) (Units on scale) on day 20
Primary PaO2 on day 20 pressure of oxygen (PaO2) on day 20 (mm Hg) on day 20
Primary PaCO2 on day 20 partial pressure of carbon dioxide (PaCO2) (mm Hg) on day 20
Secondary clinical success on day 10 Proportion of patients were clinically successful on day 10 (%) on day 10
Secondary FEV1 on day 10 Percent Predicted forced expiratory volume in one second [FEV1] on day 10 (%) on day 10
Secondary FVC on day 10 Percent Predicted forced vital capacity (FVC) on day 10 (%) on day 10
Secondary serum CRP on day 10 Concentration of serum CRP on day 10 on day 10 (mg/L) on day 10
Secondary WBC on day 10 white blood cell count on day 10 (10x109/L) on day 10
Secondary VAS on day 10 the visual analogue scale (VAS) on day 10 (Units on scale) on day 10
Secondary PaO2 on day 10 pressure of oxygen (PaO2) on day 10 (mm Hg) on day 10
Secondary PaCO2 on day 10 partial pressure of carbon dioxide (PaCO2) on day 10 (mm Hg) on day 10
See also
  Status Clinical Trial Phase
Terminated NCT05418777 - Treatment of Pneumocystis in COPD (the TOPIC Study) Phase 1/Phase 2
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Completed NCT03286855 - Effectiveness of Vibrating Mesh Versus Small Volume Nebuliser in Chronic Obstructive Pulmonary Disease (COPD) N/A
Recruiting NCT06021990 - Clopidogrel for the Prevention of Exacerbations in Severe COPD Phase 3
Completed NCT05218525 - Testing a Prediction Algorithm Into a Running Telehealth System for Patients With COPD N/A
Recruiting NCT06149494 - RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection Phase 2
Recruiting NCT05734365 - COPD-ICU Multicentre Prospective Observational Register
Completed NCT03464695 - Automated Oxygen Delivery by O2matic to Patients Admitted With an Exacerbation in COPD N/A
Recruiting NCT04881409 - Nasal High-flow Compared to Non-invasive Ventilation in Treatment of Acute Acidotic Hypercapnic Exacerbation of Chronic Obstructive Pulmonary Disease N/A
Completed NCT05182294 - Tolerance and Acute Effects of a New HFNT Nasal Cannula N/A
Completed NCT04821869 - ProAir Digihaler in COPD Disease Management: A Real World Study
Recruiting NCT06274957 - The Effect of Airway and Chest Wall Oscillation on Respiratory Functions in COPD Patients in Acute Exacerbation N/A
Recruiting NCT05783544 - Impact of A. Lumbricoides on Pulmonary Aspergillosis Development N/A
Recruiting NCT06331416 - Multiparametric Home Telemonitoring of Patients With Chronic Obstructive Pulmonary Disease Exacerbation N/A
Not yet recruiting NCT05703919 - Standard vs Targeted Oxygen Therapy Prehospital for Chronic Obstructive Pulmonary Disease Phase 4
Not yet recruiting NCT06419036 - The Use of Medical Devices to Monitor Chronic Obstructive Pulmonary Disease Patients Study BREATH-TRACHER 1
Not yet recruiting NCT06419062 - The Use of Medical Devices to Monitor Chronic Obstructive Pulmonary Disease Patients Study BREATH-TRACHER 2
Recruiting NCT05764993 - Prevalence of Humoral Dysfunction in Pts With Frequent Exacerbations of COPD, and the Effect of SCIgR for Prevention Phase 2
Completed NCT06040931 - Airway Inflammation, Small Airways Dysfunction, and Frequency of Exacerbations in COPD N/A
Active, not recruiting NCT04192175 - Identification of Patients Admitted With COPD Exacerbations and Predicting Readmission Risk Using Machine Learning